Healthcare Industry News: Clearside Biomedical
News Release - February 25, 2013
Clearside Biomedical, Inc. Names Rafael V. Andino Vice President, Product DevelopmentALPHARETTA, Ga.--(Healthcare Sales & Marketing Network)--Clearside Biomedical, Inc., a privately held ophthalmic company developing and commercializing targeted therapeutics for the treatment of sight-threatening diseases, today announced Rafael V. Andino has been named to the position of Vice President, Product Development.
Andino has 25 years of experience in the pharmaceutical and medical device industry in both public and private companies serving in product development, research and development and general management roles. He has led multidisciplinary and multinational teams to launch successful products in many fields of medicine including ophthalmology, urology, endourology, gynecology, wound care, cardiovascular and general surgery.
“Rafael’s product development and leadership experience and his proven ability to bring new products to market will be an invaluable asset to us, and he will play an integral role in the leadership team we are building at Clearside Biomedical,” said Daniel White, president and CEO.
Andino has most recently been employed as Director of R&D by Bard Medical, a division of C.R. Bard, Inc., a top 20 global medical device manufacturer with sales in excess of $2.5 billion (BCR). Prior to Bard, he founded and led Biofisica, Inc. which developed breakthrough technology to expedite wound healing and regeneration of connective tissue in humans. In 2007, Biofisica launched the first wound care product of its kind, POSIFECT®, in the United Kingdom. Prior to founding Biofisica, Andino was a R&D director and senior project manager for CIBA VISION® (a Novartis company), a leading global contact lens and lens care company. He has also worked for the global technology companies E.I. Dupont, General Electric and IBM.
Andino obtained a Bachelor’s degree in Mechanical Engineering from the Georgia Institute of Technology, a Master of Science in Biomedical Engineering from the University of Alabama at Birmingham and an MBA from Mercer University in Atlanta, GA.
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc., headquartered in Alpharetta, GA is a clinical-stage ophthalmic pharmaceutical company that develops and commercializes targeted therapeutics to treat sight-threatening diseases. Clearside treats the pathological changes to the blood retinal barrier that lead to retinal blindness by delivering therapeutics through the suprachoroidal space to the retina and choroid using a proprietary microinjection dosage form. Clearside Biomedical was founded by an executive team with extensive development and revenue growth expertise. This team strives for better delivery and performance of its therapeutic agents to improve the standard of care for patients with retinal and choroidal disease. Visit http://www.clearsidebio.com/ for more information.
Source: Clearside Biomedical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsBausch Health Licenses Clearside Biomedical's XIPERE(TM) (Triamcinolone Acetonide Suprachoroidal Injectable Suspension), An Investigational Treatment For Macular Edema Associated With Uveitis
REGENXBIO Announces Exclusive Worldwide Option and License Agreement with Clearside Biomedical for Evaluation of In-Office Delivery Platform for RGX-314